The competitive landscape of the Imatinib Drug Market is sharply bifurcated between the original innovator company and the multitude of generic manufacturers that entered post-patent expiry. Novartis AG, the originator and brand holder (Gleevec/Glivec), continues to maintain a significant presence, capitalizing on brand loyalty, historical market penetration, and premium pricing in specific...